NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Prescribing
  • Key to symbols

6 Endocrine system

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens

Preferred list
Total Formulary

Restrictions: Restricted to specialist initiation.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4405.htm


Restrictions: Somatropin for use in adults with growth hormone deficiency is restricted to initiation by consultant endocrinologists. The treatment of growth disturbance in short children born small for gestational age and who have failed to show catch-up growth by 4 years of age or later is restricted to initiation and monitoring by a paediatrician with expertise in managing childhood growth disorders and growth hormone therapy.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4411.htm


Restrictions: Restricted to specialist use only.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4417.htm


Restrictions: Restricted to specialist initiation.


Restrictions: Restricted to specialist initiation.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106141.htm


Restrictions: Restricted to specialist initiation.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4401.htm

FOLLITROPIN ALFA (sub-cutaneous injection)

Restrictions: Restricted to specialist use for the indications listed in the Prescribing Notes section below:

Prescribing Notes:

In adult women for:

  • anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate.
  • stimulation of multi-follicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intrafallopian transfer and zygote intra-fallopian transfer.
  • in association with a luteinising hormone (LH) preparation for the stimulation of follicular development in women with severe LH and follicle-stimulating hormone (FSH) deficiency. In clinical trials these patients were defined by an endogenous serum LH level <1.2 units/L.

In adult men for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hCG) therapy.

The BNF recommends that is is good practice to prescribe biosimilars by brand name.

BNF Link: https://www.medicinescomplete.com/mc/bnf/current/PHP4581-follitropin-alfa-and-beta.htm?q=follitropin&t=search&ss=text&p=1#_hit



Restricted to specialist use only for the treatment of adults with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 (insulin-like growth factor 1) concentrations or was not tolerated.


Restrictions: Restricted tp specialist initiation.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4397.htm

6.5.2 Posterior pituitary hormones and antagonists

Preferred list
DESMOPRESSIN (excludes oral lyophilisate)


Desmopressin tablets are restricted to use in patients unable to use intramuscular preparations. Intravenous desmopressin is restricted to use in specialist haemophilia centres.

Prescribing Notes:

  • Used for treatment of diabetes insipidus, primary nocturnal enuresis and postoperative polyuria or polydipsia. Due to the high level of adverse reactions, desmopressin nasal spray is no longer indicated for primary nocturnal enuresis. Oral formulations should be considered as an alternative.
  • For use in the symtomatic treatment of nocturia due to idiopathic nocturnal polyuria see section 7.4.2

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4431.htm

Total Formulary

Restrictions: Restricted to specialist initiation.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/3814.htm


Restrictions: Restricted to specialist use only.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4436.htm


Restrictions: Restricted to specialist use to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

Prescribing Notes:

Prescribing and associated monitoring of this medicine is to be carried out within the acute sector.

Use of tolvaptan for the treatment of SIADH is not recommended for use in NHSScotland by the SMC and is non-Formulary.